Content deleted Content added
No edit summary |
No edit summary |
||
| Line 20: | Line 20: | ||
}} |
}} |
||
'''Org 28312''' is a drug developed by [[Organon International]] which acts as a potent [[cannabinoid]] [[Receptor (biochemistry)|receptor]] [[full agonist]] at both the [[Cannabinoid receptor 1|CB<sub>1</sub>]] and [[Cannabinoid receptor 2|CB<sub>2</sub>]] receptors. It was developed with the aim of finding a [[solubility|water soluble]] cannabinoid agonist suitable for [[intravenous]] use as an [[analgesic]], but did not proceed to human trials, with the related compound [[Org 28611]] chosen instead due to its better penetration into the brain.<ref>{{Cite doi|10.1039/c0md00022a}}</ref> These compounds have subsequently been investigated further leading to the development of a number of more potent analogues, derived by cyclisation around either the indole or piperazine rings.<ref name="pmid20634067">{{cite journal |author=Kiyoi T, York M, Francis S, Edwards D, Walker G, Houghton AK, Cottney JE, Baker J, Adam JM |title=Design, synthesis, and structure-activity relationship study of conformationally constrained analogs of indole-3-carboxamides as novel CB1 cannabinoid receptor agonists |journal=Bioorganic & Medicinal Chemistry Letters |volume=20 |issue=16 |pages=4918–21 |year=2010 |month=August |pmid=20634067 |doi=10.1016/j.bmcl.2010.06.067 |url=}}</ref><ref name="pmid21074434">{{cite journal |author=Moir EM, Yoshiizumi K, Cairns J, Cowley P, Ferguson M, Jeremiah F, Kiyoi T, Morphy R, Tierney J, Wishart G, York M, Baker J, Cottney JE, Houghton AK, McPhail P, Osprey A, Walker G, Adam JM |title=Design, synthesis, and structure-activity relationship study of bicyclic piperazine analogs of indole-3-carboxamides as novel cannabinoid CB1 receptor agonists |journal=Bioorganic & Medicinal Chemistry Letters |volume=20 |issue=24 |pages=7327–30 |year=2010 |month=December |pmid=21074434 |doi=10.1016/j.bmcl.2010.10.061 |url=}}</ref> |
'''Org 28312''' is a drug developed by [[Organon International]] which acts as a potent [[cannabinoid]] [[Receptor (biochemistry)|receptor]] [[full agonist]] at both the [[Cannabinoid receptor 1|CB<sub>1</sub>]] and [[Cannabinoid receptor 2|CB<sub>2</sub>]] receptors. It was developed with the aim of finding a [[solubility|water soluble]] cannabinoid agonist suitable for [[intravenous]] use as an [[analgesic]], but did not proceed to human trials, with the related compound [[Org 28611]] chosen instead due to its better penetration into the brain.<ref>{{Cite doi|10.1039/c0md00022a}}</ref> These compounds have subsequently been investigated further leading to the development of a number of more potent analogues, derived by cyclisation around either the [[indole]] or [[piperazine]] rings.<ref name="pmid20634067">{{cite journal |author=Kiyoi T, York M, Francis S, Edwards D, Walker G, Houghton AK, Cottney JE, Baker J, Adam JM |title=Design, synthesis, and structure-activity relationship study of conformationally constrained analogs of indole-3-carboxamides as novel CB1 cannabinoid receptor agonists |journal=Bioorganic & Medicinal Chemistry Letters |volume=20 |issue=16 |pages=4918–21 |year=2010 |month=August |pmid=20634067 |doi=10.1016/j.bmcl.2010.06.067 |url=}}</ref><ref name="pmid21074434">{{cite journal |author=Moir EM, Yoshiizumi K, Cairns J, Cowley P, Ferguson M, Jeremiah F, Kiyoi T, Morphy R, Tierney J, Wishart G, York M, Baker J, Cottney JE, Houghton AK, McPhail P, Osprey A, Walker G, Adam JM |title=Design, synthesis, and structure-activity relationship study of bicyclic piperazine analogs of indole-3-carboxamides as novel cannabinoid CB1 receptor agonists |journal=Bioorganic & Medicinal Chemistry Letters |volume=20 |issue=24 |pages=7327–30 |year=2010 |month=December |pmid=21074434 |doi=10.1016/j.bmcl.2010.10.061 |url=}}</ref> |
||
==See also== |
==See also== |
||
Revision as of 08:35, 17 January 2011
 | |
| Identifiers | |
|---|---|
| |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C24H35N3O2 |
| Molar mass | 397.552 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
Org 28312 is a drug developed by Organon International which acts as a potent cannabinoid receptor full agonist at both the CB1 and CB2 receptors. It was developed with the aim of finding a water soluble cannabinoid agonist suitable for intravenous use as an analgesic, but did not proceed to human trials, with the related compound Org 28611 chosen instead due to its better penetration into the brain.[1] These compounds have subsequently been investigated further leading to the development of a number of more potent analogues, derived by cyclisation around either the indole or piperazine rings.[2][3]
See also
References
- ^ Attention: This template ({{cite doi}}) is deprecated. To cite the publication identified by doi:10.1039/c0md00022a, please use {{cite journal}} (if it was published in a bona fide academic journal, otherwise {{cite report}} with
|doi=10.1039/c0md00022ainstead. - ^ Kiyoi T, York M, Francis S, Edwards D, Walker G, Houghton AK, Cottney JE, Baker J, Adam JM (2010). "Design, synthesis, and structure-activity relationship study of conformationally constrained analogs of indole-3-carboxamides as novel CB1 cannabinoid receptor agonists". Bioorganic & Medicinal Chemistry Letters. 20 (16): 4918–21. doi:10.1016/j.bmcl.2010.06.067. PMID 20634067.
{{cite journal}}: Unknown parameter|month=ignored (help)CS1 maint: multiple names: authors list (link) - ^ Moir EM, Yoshiizumi K, Cairns J, Cowley P, Ferguson M, Jeremiah F, Kiyoi T, Morphy R, Tierney J, Wishart G, York M, Baker J, Cottney JE, Houghton AK, McPhail P, Osprey A, Walker G, Adam JM (2010). "Design, synthesis, and structure-activity relationship study of bicyclic piperazine analogs of indole-3-carboxamides as novel cannabinoid CB1 receptor agonists". Bioorganic & Medicinal Chemistry Letters. 20 (24): 7327–30. doi:10.1016/j.bmcl.2010.10.061. PMID 21074434.
{{cite journal}}: Unknown parameter|month=ignored (help)CS1 maint: multiple names: authors list (link)